Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 320,066
  • Shares Outstanding, K 60,965
  • Annual Sales, $ 1,560 K
  • Annual Income, $ -62,680 K
  • 60-Month Beta 0.31
  • Price/Sales 201.91
  • Price/Cash Flow N/A
  • Price/Book 3.03
Trade LYRA with:

Options Overview Details

View History
  • Implied Volatility 206.74% ( +3.56%)
  • Historical Volatility 64.62%
  • IV Percentile 94%
  • IV Rank 72.48%
  • IV High 281.62% on 04/18/24
  • IV Low 9.57% on 05/16/23
  • Put/Call Vol Ratio 0.07
  • Today's Volume 273
  • Volume Avg (30-Day) 350
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 6,351
  • Open Int (30-Day) 4,321

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.28
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +24.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.68 +3.42%
on 04/30/24
5.83 -16.98%
on 04/03/24
-0.77 (-13.73%)
since 04/02/24
3-Month
4.46 +8.52%
on 02/09/24
6.79 -28.72%
on 03/27/24
+0.16 (+3.42%)
since 02/02/24
52-Week
2.36 +105.08%
on 05/26/23
6.79 -28.72%
on 03/27/24
+2.11 (+77.29%)
since 05/02/23

Most Recent Stories

More News
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...

ASRT : 1.0000 (+8.55%)
LYRA : 4.77 (-9.14%)
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYEL : 2.39 (+2.58%)
LYRA : 4.77 (-9.14%)
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TBPH : 9.27 (+4.86%)
LYRA : 4.77 (-9.14%)
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PTCT : 34.07 (-0.26%)
LYRA : 4.77 (-9.14%)
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

SAGE : 13.04 (-1.81%)
LYRA : 4.77 (-9.14%)
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYRA : 4.77 (-9.14%)
GANX : 2.92 (-1.68%)
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company, Lyra or Lyra Therapeutics), a clinical-stage therapeutics company leveraging its...

LYRA : 4.77 (-9.14%)
LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform...

LYRA : 4.77 (-9.14%)
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYRA : 4.77 (-9.14%)
PRPH : 5.30 (+2.12%)
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)("Lyra" or the "Company"), a clinical-stage therapeutics company leveraging its proprietary XTreo™...

LYRA : 4.77 (-9.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and...

See More

Key Turning Points

3rd Resistance Point 6.25
2nd Resistance Point 5.95
1st Resistance Point 5.60
Last Price 4.77
1st Support Level 4.95
2nd Support Level 4.65
3rd Support Level 4.30

See More

52-Week High 6.79
Fibonacci 61.8% 5.10
Last Price 4.77
Fibonacci 50% 4.57
Fibonacci 38.2% 4.05
52-Week Low 2.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar